Back to compounds

COMPOUND PROFILE / SMALL MOLECULES

Lotiglipron.

Research draft

Lotiglipron is an oral small-molecule GLP-1 receptor agonist whose development was stopped.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Lotiglipron is an oral small-molecule GLP-1 receptor agonist whose development was stopped.

CLASSIFICATIONSmall molecules
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It activates GLP-1 signalling through a non-peptide structure.

Human research

Phase 1 and phase 2 studies measured metabolic responses, but the programme encountered safety and exposure concerns.

Preclinical & other research

Receptor studies informed development.

Safety & unknowns

Elevated liver enzymes and pharmacokinetic findings contributed to discontinuation.

Regulatory status

Discontinued investigational programme; it should not be presented as an available approved therapy.

Reported use & evidence

Research profile draft

The supplied Lotiglipron profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds